Traditional chinese medicine mulberry leaves polysaccharide and eucommia polysaccharide immunostimulant and application thereof
10039824 ยท 2018-08-07
Inventors
- Chunmao Jiang (Taizhou, CN)
- Xiaolan Chen (Taizhou, CN)
- Deyun Wang (Taizhou, CN)
- Haifeng Yang (Taizhou, CN)
- Caihong Wu (Taizhou, CN)
- Yi Zheng (Taizhou, CN)
- Jianhua Dai (Taizhou, CN)
- Wei Chen (Taizhou, CN)
- Xianglai He (Taizhou, CN)
Cpc classification
A61K36/46
HUMAN NECESSITIES
C12N2770/10034
CHEMISTRY; METALLURGY
C12N7/00
CHEMISTRY; METALLURGY
C12N2760/18134
CHEMISTRY; METALLURGY
A61K36/46
HUMAN NECESSITIES
A61K39/39
HUMAN NECESSITIES
C08B37/0003
CHEMISTRY; METALLURGY
A61K2300/00
HUMAN NECESSITIES
A61K2300/00
HUMAN NECESSITIES
International classification
A61K36/00
HUMAN NECESSITIES
A61K36/46
HUMAN NECESSITIES
A61K39/39
HUMAN NECESSITIES
C12N7/00
CHEMISTRY; METALLURGY
Abstract
A traditional Chinese medicine immunopotentiator prepared from mulberry leaves polysaccharide and eucommia polysaccharide. The immunopotentiator can stimulate proliferation of chicken lymphocytes in vitro. When used together with newcastle disease vaccine to immunize chickens, the immunopotentiator can increase serum antibody titer, promote proliferation of lymphocytes, and enhance cellular immunity and humoral immunity of the chickens. When used together with porcine productive and respiratory syndrome vaccine to immunize piglets, the immunopotentiator can increase the serum antibody titer. When used together with the porcine productive and respiratory syndrome vaccine to immunize layers, the immunopotentiator can increase porcine productive and respiratory syndrome virus yolk antibody titer and improve immune effects of the vaccine.
Claims
1. A traditional Chinese medicine immunopotentiator, characterized in that it is prepared from mulberry leaves polysaccharide and eucommia polysaccharide, each 1000 ml of the immunopotentiator is prepared from 150 g of mulberry leaves and 140 g of eucommia bark; the immunopotentiator comprises or comprises no additional Chinese traditional medicine extract; the immunopotentiator contains no other chemical active ingredients; processes of producing each 1000 ml of medicinal liquid are as follows: decoding mulberry leaves with water for 2 times, ethanol precipitation, drying ethanol sediments, dissolving with 640 mL of water, and obtaining mulberry leaves polysaccharide solution; degreasing eucommia, ethanol precipitation, drying ethanol sediments, dissolving with water, and obtaining eucommia polysaccharide solution, mixing the mulberry leaves polysaccharide solution and the eucommia polysaccharide solution evenly, subpackaging and obtaining the medicinal liquid; extraction process of mulberry leaves polysaccharide is: adding 30 times of water to decoct the mulberry leaves for 2 times, 1.5 hour for a first time and 1hour for a second time; extraction process of eucommia polysaccharide are: adding 4 times of absolute ethyl alcohol to perform reflux degreasing to the eucommia bark for 2 times and decocting with water for 2 times, 1.5 hours for a first time and 1 hour for a second time.
2. The traditional Chinese medicine immunopotentiator according to claim 1, characterized in that a content of mulberry leaves polysaccharide in medicinal liquid is between 0.2-0.6% and a weight percentage of the eucommia polysaccharide is between 0.1-0.5%.
3. A vaccine kit, characterized in that the vaccine kit comprises the traditional Chinese medicine immunopotentiator of claim 1.
4. The vaccine kit according to claim 3, wherein the vaccine kit comprises newcastle disease vaccine, the traditional Chinese medicine immunopotentiator is existed in the vaccine kit at a rate of each unit dose of the vaccine and 1 ml traditional Chinese medicine immunopotentiator.
5. An application of the traditional Chinese medicine immunopotentiator according to claim 1 in preparing medicines enhancing vaccine immunity; wherein the vaccine is newcastle disease vaccine.
Description
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
(1) 1. Preparation Process
(2) (1) the preparation of mulberry leaves polysaccharide is taking mulberry leaves polysaccharide yield in extract as index, carrying out orthogonal test to water addition, extraction time, extraction times, and ethanol concentration for ethanol precipitation, and determining the best extraction process of the mulberry leaves polysaccharide is adding 30 times of water, decocting for 2 times, 1.5 h for the first time and lh for the second time. Taking 150 g of mulberry leaves, water decocting by above process, merging of filtrates, adding 95% of ethanol so that ethanol content can reach 75%, still standing for 12 h, precipitating, drying under 65 DEG C, dissolving with 640 mL of water and obtaining mulberry leaves polysaccharide water solution.
(3) (2) the preparation of eucommia polysaccharide is taking eucommia polysaccharide yield in extract as index, carrying out orthogonal test to degreasing ethanol content, water addition, extraction time, and extraction times, and determining the best extraction process of the eucommia polysaccharide is adding 4 time of 95% of ethanol to perform reflux degreasing for 2 times, adding 20 time of water to decoct for 2 times, 1.5 h for the first time and 1 h for the second time, Taking 145 g of eucommia bark and degreasing by above process, water decocting, merging of filtrates, adding 95% of ethanol so that ethanol content can reach 75%, still standing for 12 h, precipitating, drying under 65 DEG C, dissolving with 360 mL of water and obtaining mulberry leaves polysaccharide water solution.
(4) (3) the preparation of the medicinal liquid is mixing the mulberry leaves polysaccharide solution and eucommia polysaccharide solution, and subpackaging. The polysaccharide content is determined by phenol-sulfuric acid method, and the content of rutin and pinoresinol diglucoside is determined by HPLC method. The polysaccharides content in the medicinal liquid is not lower than 0.3%, rutin content is not lower than 0.025% and the content of pinoresinol diglucoside is not lower than 0.01%.
(5) 2. Comparison of Enhancing Immune Effect
(6) (1) Enhancing Immune Effect in Virtu
(7) Taking the immunopotentiator prepared from mulberry leaves polysaccharide and eucommia polysaccharide as test materials, preparing contrast prescription 1 (mulberry leaves extract and eucommia polysaccharide) and contrast prescription 2 (mulberry leaves polysaccharide and 2 parts of eucommia extract), first determining the safe concentration of three prescriptions to peripheral blood lymphocyte of chickens, diluting three prescriptions with cell culture medium (RPMI 1640) into 5 working concentrations, that is, 250 g/mL.sup.1, 125 g/mL.sup.1, 62.5 g/mL.sup.1, 31.25 g/mL.sup.1 and 15,625 g/mL.sup.1 respectively, adding into cultured peripheral blood lymphocyte of chickens respectively, determining lymphocyte proliferation (A.sub.570 value) by MTT method, taking A.sub.570 value as index of lymphocyte proliferation, and calculating Stimulation Index (SI) of lymphocyte to compare the effect of three prescriptions based on formula: SI (medicine group A.sub.570 value minus cell con
(8) Result: 1) change of lymphocyte proliferation: when the concentration of the immunopotentiator prepared from mulberry leaves polysaccharide and eucommia polysaccharide is 250 g/mL.sup.1, 125 g/mL.sup.1, 62.5 g/mL.sup.1, and 31.25 g/mL.sup.1, A.sub.570 values of the immunopotentiator are much higher than that of the cell control group (P<0.05), and when the concentration of the contrast prescription 1 and the contrast prescription 2 is 50 g/mL.sup.1, 125 g/mL.sup.1, and 62.5 /mL.sup.1, A.sub.570 values of the contrast prescription 1 and the contrast prescription 2 are much higher than that of the cell control group (P<0.05).
(9) TABLE-US-00001 TABLE 1 CHANGE OF LYMPHOCYTE PROLIFERATION OF EACH GROUP (A.sub.570 VALUE) Con- centration Contrast Contrast (g .Math. mL.sup.1) Immunopotentiator prescription 1 prescription 2 250 0.324 0.003.sup.ab 0.280 0.003.sup.b 0.290 0.004.sup.b 125 0.329 0.001.sup.a 0.295 0.002.sup.ab 0.298 0.005.sup.ab 62.5 0.312 0.003.sup.b 0.306 0.003.sup.a 0.307 0.003.sup.a 31.25 0.280 0.001.sup.c 0.263 0.006.sup.c 0.265 0.004.sup.c 15.625 0.252 0.002.sup.de 0.249 0.003.sup.cd 0.251 0.007.sup.cd Cell control 0.245 0.003.sup.e 0.245 0.003.sup.cd 0.245 0.003.sup.cd group Note: marks without containing the same letter within the same line have significant difference(P < 0.05), so do the following tables.
(10) 2) Comparison of lymphocyte simulation index: when the concentration of the immunopotentiator prepared from mulberry leaves polysaccharide and eucommia polysaccharide is 250 g/mL.sup.1, 125 g/mL.sup.1, 62.5 g/mL.sup.1, and 31.25 g/mL.sup.1, the simulation index of the immunopotentiator is much higher than that of two contrast prescription groups (P<0.05), when the concentration of the immunopotentiator is 15.625 g/mL.sup.1, the simulation index of the immunopotentiator is a little higher than that of two contrast prescription groups (Table 2).
(11) TABLE-US-00002 TABLE 2 COMPARISON OF LYMPHOCYTE PROLIFERATION EFFECT SIMULATION OF EACH PRESCRIPTION (SI) Concentration (g .Math. mL.sup.1) Groups 250 125 62.5 31.25 15.625 Immuno- 1.321 0.031.sup.a 1.342 0.011.sup.a 1.273 0.031.sup.a 1.143 0.011.sup.a 1.029 0.024.sup.a potentiator Contrast 1.142 0.033.sup.b 1.205 0.022.sup.b 1.251 0.032.sup.b 1.073 0.04.sup.b 1.018 0.033.sup.a prescription 1 Contrast 1.183 0.041.sup.b 1.216 0.051.sup.b 1.253 0.031.sup.b 1.082 0.041.sup.b 1.024 0.031.sup.a prescription 2
(12) 2) Enhancing Immune Test in Vivo
(13) Method: taking the immuncpotentiator prepared from mulberry leaves polysaccharide and eucommia polysaccharide as test materials, preparing contrast prescription 1 (mulberry leaves extract and eucommia polysaccharide) and contrast prescription 2 (mulberry leaves polysaccharide and 2 parts of eucommia extract). Taking 150 14-day-old nonimmune and healthy Roman chickens, dividing into 5 groups randomly, dropwise adding 2 plumes of the newcastle disease IV vaccine into nose and eyes of each chicken except the Blank Control (BC) group to carry out first immunization, and carrying out second immunization on 28-day-old. At the same time of the first immunization and the second immunization, drinking water and administering corresponding drugs for 3 days for the chickens of three groups of traditional Chinese medicine, and drinking freely for the chickens of Vaccine Control (VC) and BC, and selecting six chickens of each group randomly on the 7.sup.th day (D.sub.7), 14.sup.th day (D.sub.14), 21th day (D.sub.21 ) and 28.sup.th day (D.sub.28) after immunization, collecting blood, separating serum, detecting ND-HI antibody titer by -micromethod, and determining peripheral blood T lymphocyte proliferation by MTT method.
(14) Result:
(15) 1) The antibody titer of the immunopotentiator prepared from mulberry leaves polysaccharide and eucommia polysaccharide at different time points after immunization is the highest, on D.sub.14 after first immunization, the antibody tier is 0.53 titer higher than that of contrast prescription 2, and is much higher than that of other groups (P<0,05): on D.sub.21 after first immunization, the antibody titer of the immunopotentiator is much higher than that of other groups, 1.43 titer higher than that of contrast prescription 1 and 1.09 titer higher than that of contrast prescription 2 respectively; on D.sub.28 after first immunization, the antibody titer of the immunopotentiator is much higher than that of other groups, 1.43 titer higher than that of contrast prescription 1 and 1.23 titer higher than that of contrast prescription 2 respectively (Table 3) , which shows the immunopotentiator prepared from mulberry leaves polysaccharide and eucommia polysaccharide can increase serum antibody titer greatly, and its effect is superior than other two contrast prescriptions.
(16) TABLE-US-00003 TABLE 3 DYNAMIC CHANGE OF ANTIBODY TITER OF EACH GROUP Groups D.sub.7 D.sub.14 D.sub.21 D.sub.28 Immuno- 4.78 0.32 55.16 0.23.sup.a 7.21 0.33.sup.a 6.77 0.28.sup.a potentiator Contrast 4.21 0.21 4.29 0.31.sup.b 5.78 0.42.sup.bc 5.34 0.32.sup.b prescrip- tion 1 Contrast 4.59 0.31 4.63 0.32.sup.ab 6.12 0.32.sup.bc 5.54 0.21.sup.b prescrip- tion 2 VC 3.82 0.23 3.64 0.31.sup.c 5.09 0.33.sup.c 4.34 0.27.sup.c BC 2.48 0.21 2.29 0.33.sup.d 2.15 0.21.sup.d 2.14 0.21.sup.d
(17) 2) Change of Lymphocyte Proliferation
(18) The A.sub.570 value of the immunopotentiator prepared from mulberry leaves polysaccharide and eucommia polysaccharide at 4 time points after first immunization is the highest, on D.sub.7 after first immunization, the A.sub.570 value is much higher than that of VC and BC (PK0.05), and a little higher than that of two contrast prescriptions; on D.sub.14 and D.sub.28 after first immunization, the A.sub.570 value is, much higher than that of contrast prescription 1 (P<0.05), and a little higher than that of contrast prescription 2; and on D.sub.21 after first immunization, the A.sub.570 value is much higher than that of other groups (P<0.05) (Table 4).
(19) TABLE-US-00004 TABLE 4 DYNAMIC CHANGE OF LYMPHOCYTE PROLIFERATION OF EACH GROUP (A.sub.570) Groups D.sub.7 D.sub.14 D.sub.21 D.sub.28 Immuno- 0.257 0.006.sup.a 0.313 0.012.sup.a 0.319 0.005.sup.a 0.291 0.013.sup.a potentiator Contrast 0.252 0.012.sup.ab 0.289 0.008.sup.b 0.298 0.007.sup.b 0.278 0.005.sup.b prescription 1 Contrast 0.250 0.007.sup.ab 0.301 0.013.sup.ab 0.301 0.012.sup.b 0.285 0.007.sup.ab prescription 2 VC 0.207 0.005.sup.c 0.238 0.011.sup.c 0.253 0.003.sup.c 0.241 0.0074.sup.c BC 0.172 0.021.sup.d 0.1831 0.009.sup.d 0.179 0.011.sup.d 0.202 0.004.sup.d
(20) Above results show when used together with newcastle'-disease vaccine to immunize chickens, the immunopotentiator can promote proliferation of lymphocytes, enhance cellular immunity of the chickens, and improve immune effects of the newcastle disease vaccine.
(21) 3. Selecting the best dose of the immunopotentiator prepared from mulberry leaves polysaccharide and eucommia polysaccharide
(22) Method: taking 210 14-day-old nonimmune and healthy Roman chickens, dividing into 9 groups randomly, dropwise adding 2 plumes of the newcastle disease IV vaccine into nose and eyes of each chicken except the Blank Control (BC) group to carry out first immunization, and carrying out second immunization on 28-day-old. At the same time of first immunization and second immunization, drinking water and administering corresponding drugs for 3 days based on 8 mg, 6 mg, 4 mg, 2 mg and 1 mg for each cock of 5 dose groups, and drinking freely for the chickens of Vaccine Control (VC) and BC, and selecting six cocks of each group randomly on D.sub.7, D.sub.14, D.sub.21 and D.sub.28 after immunization, collecting blood, separating serum, detecting ND-HI antibody titer by -micromethod, and determining peripheral blood T lymphocyte proliferation by MTT method.
(23) Result: 1) change of serum antibody titer: the antibody titer of each dose group of the immunopotentiator prepared from mulberry leaves polysaccharide and eucommia polysaccharide at different time points is much higher than that of VC and BC. On D.sub.7 after first immunization, the antibody titer of 4 mg dose group is the highest, much higher than 2 mg and 1 mg dose group (P<0.05); on D.sub.14 after first immunization, the antibody titer of 6 mg dose group is the highest, and the antibody titer of 4 mg does group, 6 mg does group and 8 mg does group are all much higher than that of other groups (P<0.05); on D.sub.21 and D.sub.28 after first immunization, the antibody titer of 4 mg does group, much higher than other groups (P <0.05) (Table 5).
(24) TABLE-US-00005 TABLE 5 CHANGE OF SERUM ND-HI ANTIBODY TITER OF EACH GROUP (LOG.sub.2) Groups D.sub.7 D.sub.14 D.sub.21 D.sub.28 8 mg 4.92 0.33.sup.a 5.16 0.23.sup.a 6.52 0.31.sup.b 5.74 0.21.sup.b 6 mg 4.79 0.32.sup.ab 5.31 0.32.sup.a 6.84 0.42.sup.b 6.12 0.32.sup.b 4 mg 4..98 0.23.sup.a 5.28 0.26.sup.a 7.25 0.34.sup.a 6.76 0.34.sup.a 2 mg 4.50 0.37.sup.b 4.86 0.26.sup.b 6.18 0.21.sup.b 5.49 0.32.sup.bc 1 mg 4.33 0.21.sup.b 4.77 0.35.sup.b 5.33 0.22.sup.c 5.11 0.17.sup.c VC 3.78 0.25.sup.c 4.34 0.33.sup.c 5.09 0.27.sup.c 4.77 0.24.sup.d BC 2.39 0.23.sup.d 2.31 0.37.sup.d 2.13 0.21.sup.d 2.15 0.33.sup.e
(25) 2) Change of lymphocyte proliferation: the A.sub.570 value of each dose group of the immunopotentiator prepared from mulberry leaves polysaccharide and eucommia polysaccharide at different time points is much higher than that of VC and BC. On D.sub.7 after first immunization, A.sub.570 values of three dose groups of the immunopotentiator are all much higher than that of VC (P<0.05): on D.sub.14, A.sub.570 values of 4 mg dose group and 6 mg dose group are much higher than that of VC and BC(P<0.05); on D.sub.21, A570 values of 4 mg dose group and 6 mg dose group are much higher than that of other three groups (P<0.05): on D.sub.28, A.sub.570 value of 4 mg dose group are much higher than that of other groups (P<0.05) (Table 6).
(26) TABLE-US-00006 TABLE 6 CHANGE OF LYMPHOCYTE PROLIFERATION Groups D.sub.7 D.sub.14 D.sub.21 D.sub.28 6 mg 0.212 0.002.sup.ab 0.226 0.003.sup.a 0.224 0.007.sup.a 0.264 0.001.sup.b 4 mg 0.217 0.003.sup.a 0.235 0.007.sup.a 0.241 0.003.sup.a 0.289 0.003.sup.a 2 mg 0.203 0.004.sup.b 0.215 0.010.sup.ab 0.199 0.005.sup.b 0.265 0.002.sup.b VC 0.187 0.003.sup.c 0.193 0.004.sup.bc 0.197 0.003.sup.b 0.250 0.003.sup.b BC 0.192 0.004.sup.c 0.189 0.007.sup.c 0.167 0.001.sup.c 0.201 0.008.sup.c
(27) Above results show the immunopotentiator prepared from mulberry leaves polysaccharide and eucommia polysaccharide can increase serum antibody titer of newcastle disease vaccine to immunize chickens, promote proliferation of peripheral blood lymphocyte, and enhance cellular immunity and humoral immunity of the chickens, and improve the immune effect of newcastle disease significantly; compared with other doses, 4 mg of drinking and administration of chickens is the best.
(28) The above disclosure merely shows several specific embodiments of the invention, and the invention is not limited thereto. Any variations or substitution that may come into the mind of those skilled in the art without creative labor shall fail into the protection scope of the invention. Therefore, the protection scope of the invention shall be limited by the claims.